🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 other active

    1 trial

  2. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  3. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

    Hoffmann-La Roche

    NMDAR or LGI1 mediated autoimmune Encephalitis

    phase 3 other active

    1 trial

  4. A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

    Hoffmann-La Roche

    KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 other active

    1 trial

  5. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  6. A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 3 other active

    1 trial

  7. A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's disease.

    COLLEGIUM PHARMACEUTICAL, INC

    Anal or recto-cutaneous or recto-vaginal Crohn-related fistula

    phase 3 other active

    1 trial

  8. A matching sterile product (Placebo Ophthalmic Solution) will be provided using the same excipient formulation as the active K-321 product., Ripasudil

    The George Institute

    Fuchs Endothelial Corneal Dystrophy

    phase 3 small molecule active

    1 trial

  9. A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 other active

    1 trial

  10. A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)

    Disc Medicine

    ABC borderline resectable pancreatic cancer

    phase 3 other active

    1 trial

  11. A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

    Takeda

    Dravet and Lennox-Gastaut Syndromes

    phase 3 other active

    1 trial

  12. A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 other active

    1 trial

  13. A placebo matching Mepolizumab, Nucala 100 mg solution for injection in pre-filled syringe, A placebo matching Depemokimab, GSK3511294, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection, Nucala 100 mg solution for injection in pre-filled syringe, Fasenra 30 mg solution for injection in pre-filled syringe

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  14. A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 other active

    1 trial

  15. A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer

    Mabxience Research SL

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  16. A-101 Solution

    Aclaris Therapeutics

    Seborrheic Keratosis

    phase 3 small molecule completed

    3 trials

  17. ABBV-066 / Risankizumab, ABBV-066, Entyvio 300 mg powder for concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  18. ABBV-066 / Risankizumab, Risankizumab, Matching Placebo for 90 mg solution for injection, ABBV-066, Matching placebo for 180 mg solution for injection

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial

  19. ABBV-RGX-314 or RGX-314, ABBV-RGX-314 or RGX-314, Lucentis 10 mg/ml solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 3 small molecule active

    1 trial

  20. ABEMACICLIB , FULVESTRANT

    Eli Lilly Co.

    Breast cancer

    phase 3 small molecule active

    1 trial

  21. ABIRATERONE , DEGARELIX , Niraparib - capsule - 100 mg, RELUGOLIX , Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for Niraparib, Prednison acis 5 mg, Tabletten, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, TECHNETIUM (99MTC) COMPOUNDS, -, Abiraterone acetate - tablet - 250 mg

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  22. ABIRATERONE ACETATE, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, SYLVANT 400 mg powder for concentrate for solution for infusion, CABAZITAXEL, AMG 509, ABIRATERONE ACETATE, DOCETAXEL

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  23. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  24. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources